Intra-Cellular Therapies Operating Income 2013-2022 | ITCI

Intra-Cellular Therapies annual/quarterly operating income history and growth rate from 2013 to 2022. Operating income can be defined as income after operating expenses have been deducted and before interest payments and taxes have been deducted.
  • Intra-Cellular Therapies operating income for the quarter ending March 31, 2022 was $-0.073B, a 36.53% increase year-over-year.
  • Intra-Cellular Therapies operating income for the twelve months ending March 31, 2022 was $-0.305B, a 29.64% increase year-over-year.
  • Intra-Cellular Therapies annual operating income for 2021 was $-0.286B, a 23.55% increase from 2020.
  • Intra-Cellular Therapies annual operating income for 2020 was $-0.231B, a 50.14% increase from 2019.
  • Intra-Cellular Therapies annual operating income for 2019 was $-0.154B, a 5.09% decline from 2018.
Intra-Cellular Therapies Annual Operating Income
(Millions of US $)
2021 $-286
2020 $-231
2019 $-154
2018 $-162
2017 $-103
2016 $-118
2015 $-106
2014 $-31
2013 $-26
2012 $-16
Intra-Cellular Therapies Quarterly Operating Income
(Millions of US $)
2022-03-31 $-73
2021-12-31 $-86
2021-09-30 $-77
2021-06-30 $-69
2021-03-31 $-53
2020-12-31 $-61
2020-09-30 $-56
2020-06-30 $-65
2020-03-31 $-49
2019-12-31 $-42
2019-09-30 $-36
2019-06-30 $-39
2019-03-31 $-37
2018-12-31 $-43
2018-09-30 $-43
2018-06-30 $-39
2018-03-31 $-37
2017-12-31 $-33
2017-09-30 $-24
2017-06-30 $-19
2017-03-31 $-28
2016-12-31 $-28
2016-09-30 $-30
2016-06-30 $-32
2016-03-31 $-28
2015-12-31 $-29
2015-09-30 $-32
2015-06-30 $-22
2015-03-31 $-22
2014-12-31 $-15
2014-09-30 $-7
2014-06-30 $-5
2014-03-31 $-5
2013-12-31 $-8
2013-09-30 $-5
2013-06-30 $-8
2013-03-31 $-5
2012-12-31
2012-09-30 $-2
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $5.459B $0.084B
Intra-Cellular Therapies Inc. is a biopharmaceutical company. The company develops drugs for the treatment of neuropsychiatric and neurologic diseases and other disorders of the central nervous system. Its product candidates include ITI-007, ITI-002 and ITI-009 which is in clinical trials. Intra-Cellular Therapies Inc. is headquartered in New York.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $162.213B 9.87
Bio-Rad Laboratories (BIO.B) United States $15.121B 32.79
QIAGEN (QGEN) Netherlands $10.280B 16.23
Biohaven Pharmaceutical Holding (BHVN) United States $10.017B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.593B 0.00
Emergent Biosolutions (EBS) United States $1.775B 7.60
Arcus Biosciences (RCUS) United States $1.357B 34.40
Myovant Sciences (MYOV) United Kingdom $1.000B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.486B 0.00
Gelesis Holdings (GLS) United States $0.360B 0.00
Zymeworks (ZYME) Canada $0.346B 0.00
Ambrx Biopharma (AMAM) United States $0.149B 0.00
Enzo Biochem (ENZ) United States $0.116B 23.80
SQZ Biotechnologies (SQZ) United States $0.099B 0.00